Summary & Overview
HCPCS C9154: Buprenorphine Extended-Release (Brixadi) Injection, 1 mg
HCPCS Level II code C9154 denotes an injection of extended-release buprenorphine (Brixadi), 1 mg, used in medication‑assisted treatment for opioid use disorder. As an outpatient injectable medication, this code matters nationally because it captures billing for a long‑acting formulation that can affect adherence, clinical outcomes, and payer strategies for addiction treatment.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what the code represents, payer coverage considerations, and common billing modifiers associated with injectable drug administration. The publication provides benchmarks and policy context relevant to utilization of long‑acting buprenorphine products, reimbursement and coding guidance implications, and clinical context around use in outpatient and behavioral health settings.
The report summarizes common service lines and sites of service tied to this injectable medication, outlines typical billing scenarios, and highlights areas where payers and providers frequently require clear documentation. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code C9154 describes injection, buprenorphine extended-release (Brixadi), 1 mg. This service represents a single-dose administration of an extended-release buprenorphine formulation intended for medication-assisted treatment of opioid use disorder.
Service Type: Drug administration / Medication injection
Typical Site of Service: Outpatient clinic, ambulatory infusion center, or behavioral health clinic
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with opioid use disorder (OUD) stabilized or transitioning to long-acting medication-assisted treatment. The patient presents to an ambulatory infusion clinic, addiction treatment center, or outpatient behavioral health clinic for administration of a monthly or weekly extended-release buprenorphine injection, C9154 (buprenorphine extended-release, Brixadi, 1 mg). The clinical workflow includes pre-injection assessment for withdrawal symptoms and recent opioid use, confirmation of informed consent, review of medication history and allergies, vital signs and brief counseling, medication preparation by a licensed clinician or pharmacist, and administration via subcutaneous injection per product instructions. Observation for 15–60 minutes post-injection monitors for immediate adverse reactions, injection site complications, or signs of respiratory depression. Documentation includes medication lot number, dose in milligrams, route, site of injection, informed consent, patient tolerance, and next scheduled injection date. Typical sites of service are outpatient infusion facilities, behavioral health clinics, office-based opioid treatment (OBOT) practices, and ambulatory surgical centers when provided as part of a broader procedure or observation care.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when work required is substantially greater than usually required for this injection (e.g., complex counseling or extensive stabilization services during the visit). |